Randomised double-blind trial of bromovinyldeoxyuridine (BVDU) and trifluorothymidine (TFT) in dendritic corneal ulceration.
The results of a randomised double-blind clinical trial of 0.1% bromovinyldeoxyuridine (BVDU) and 1% trifluorothymidine (TFT) in 60 patients with corneal dendritic ulceration are presented. There was no significant difference between BVDU and TFT in terms of numbers of ulcers healed (p = 0.61), mean healing time (p = 0.065), and cumulative healing rate (p = 0.058). No serious side effects were observed, though transient stinging was recorded in five patients receiving TFT and in three patients receiving BVDU. One patient in the group treated with TFT developed a punctate epitheliopathy.
Power
W J
WJ
Professorial Unit, Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
Benedict-Smith
A
A
Hillery
M
M
Brady
K
K
Collum
L M
LM
D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D001973:Bromodeoxyuridine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D003320:Corneal Ulcer / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007635:Keratitis, Dendritic / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D014271:Trifluridine / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects
D000998:Antiviral Agents; C020235:brivudine; D001973:Bromodeoxyuridine; D014271:Trifluridine